In this issue:
Real-world CLL in Australia & NZ
Pre-clinical EZH2 + DOT1L inhibition in B-cell lymphoma
MURANO: final analysis of fixedduration venetoclax-rituximab in R/R CLL
Three molecular subtypes of CD30+ PTCL
FOLL12: prognostic utility of interim PET in follicular lymphoma
Pre-clinical data of a novel menin-KMT2A inhibitor in AML
Outcomes with CAR T-cell therapy in extranodal R/R DLBCL
Transformation to DLBCL in HL & indolent B-NHL
Next-generation BTK inhibitors in highrisk R/R CLL
Hypothetical treatment sequences for R/R T-cell & NK-cell lymphomas
Expert contributor
Dr Shafqat Inam is a consultant haematologist working in Sydney. His clinical and research focus is the application of cell and immune therapies in the treatment of lymphoma, leukaemia, and myeloma.
Stay up to date with our latest clinical information.
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.